The Atherosclerotic Cardiovascular Disease (ASCVD) market continues to expand steadily as population aging, improved post-event survival, and sustained exposure to cardiometabolic risk factors widen the long-term secondary prevention pool. According to DelveInsight's analysis, the total ASCVD market size across the 7MM — the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan — stood at approximately USD 24,000 million in 2025 and is projected to reach nearly USD 40,000 million by 2036, growing at a CAGR of 4.8% between 2026 and 2036. This sustained growth reflects both a rapidly expanding patient population and a maturing therapeutic pipeline aimed at addressing residual cardiovascular risk beyond what current standards of care can achieve.

Atherosclerotic Cardiovascular Disease Understanding

ASCVD is characterized by the buildup of fatty plaques — composed of cholesterol, fatty substances, calcium, and other cellular waste products — on the inner walls of arteries. Over time, these plaques harden and narrow the arteries, reducing blood flow to vital organs and tissues. It is a progressive, chronic condition that can affect arteries throughout the body, including those supplying the heart (coronary arteries), brain (cerebral arteries), and legs (peripheral arteries). Its most common clinical manifestations include coronary artery disease (CAD), cerebrovascular disease (stroke), and peripheral arterial disease (PAD).

Diagnosis relies on a combination of clinical evaluation, laboratory testing, genetic analysis, and imaging. Initial assessment typically includes lipid profile testing — total cholesterol, LDL-C, HDL-C, and triglycerides — supplemented by biomarkers such as apolipoproteins, hsCRP, and lipoprotein(a) in selected patients to refine cardiovascular risk. Genetic testing may be used for individuals with suspected familial hypercholesterolemia, evaluating genes such as LDLR, APOB, PCSK9, or LDLRAP1. Imaging methods including ultrasonography, CT, MRI/MRA, and invasive catheter angiography help detect arterial plaques, stenosis, or calcification, while electrocardiography can identify reduced blood flow to the heart.

As per DelveInsight's estimates, the total diagnosed prevalent cases of ASCVD across the 7MM reached 65,415,000 in 2025. In the US, approximately 55% of cases occurred in males and 45% in females, translating to around 17.3 million male and 13.8 million female cases. Disease burden rises sharply with age — in EU4 and the UK, the 65-and-above age group accounted for the highest number of diagnosed cases at approximately 15,900,000, while the lowest number of cases was observed among patients aged 18–44 years. In Japan, comorbidity-specific analysis revealed that Peripheral Artery Disease (PAD) carried the highest prevalence at approximately 1,936,000 diagnosed cases, while Acute Coronary Syndrome (ACS) accounted for the lowest at around 102,000 cases. This detailed demographic and comorbidity breakdown is a key focus of ongoing Atherosclerotic Cardiovascular Disease (ASCVD) market research, as it directly informs risk stratification, forecasting models, and commercial strategy for both established and emerging therapies.

Atherosclerotic Cardiovascular Disease Treatment Landscape and Unmet Needs

Management and prevention of ASCVD center on lifestyle modification, pharmacotherapy, and interventional procedures. A healthy lifestyle — including a balanced diet, regular physical activity, and tobacco avoidance — remains the cornerstone of risk reduction. Pharmacologic treatment is recommended for higher-risk individuals and commonly includes statins as first-line therapy, with additional agents such as ezetimibe, PCSK9 inhibitors, and omega-3 fatty acids added when lipid control remains inadequate. In patients with established disease or severe coronary blockage, revascularization procedures such as percutaneous coronary intervention or coronary artery bypass grafting may be used to restore blood flow.

Among approved PCSK9-targeted therapies, Evolocumab (REPATHA) from Amgen remains the market leader. A human IgG2 monoclonal antibody that inhibits PCSK9 from binding to the LDL receptor, REPATHA was first approved in the US and Europe in 2015, followed by Japan in 2016, with label expansions continuing through 2025 for patients at increased risk of major adverse cardiovascular events. REPATHA generated approximately USD 1,500 million in US revenue in 2025 alone — the highest of any current ASCVD therapy.

Inclisiran (LEQVIO), developed by Novartis/Alnylam Pharmaceuticals, represents a novel siRNA approach to PCSK9 inhibition, offering the advantage of twice-yearly dosing. First approved in the EU in 2020 and the US in 2021, LEQVIO has since received multiple label expansions, including a 2025 US approval for broader hypercholesterolemia populations. Alirocumab (PRALUENT) from Sanofi/Regeneron Pharmaceuticals rounds out the established PCSK9 class, with approvals spanning HeFH, HoFH, and pediatric populations as young as 8 years old.

Despite these advances in the PCSK9 inhibitor class, residual inflammatory risk, incomplete LDL-C control, comorbidity burden, and access gaps to advanced therapies remain persistent unmet needs — themes that consistently surface in current Atherosclerotic Cardiovascular Disease (ASCVD) market insight. According to KOL perspectives gathered by DelveInsight, fewer than 50% of high-risk ASCVD patients in the US remain on statin therapy at guideline-recommended intensity after the first year, and nonstatin lipid-lowering therapies such as ezetimibe, bempedoic acid, and PCSK9 inhibitors remain significantly underutilized in real-world clinical practice.

Atherosclerotic Cardiovascular Disease Pipeline and Emerging Therapies

The evolving late-stage and emerging pipeline is driving a broader shift toward multi-pathway, precision management of ASCVD, encompassing oral PCSK9 inhibitors, RNA-based Lp(a) therapies, anti-inflammatory agents, and gene-editing approaches. Olpasiran (AMG 890), an investigational siRNA therapy developed by Amgen in collaboration with Arrowhead Pharmaceuticals, is designed to reduce elevated lipoprotein(a) levels through RNA interference. The drug is currently being evaluated in two Phase III trials, alongside a Phase III primary prevention study initiated in the second half of 2025. Despite the FDA rescinding its Fast Track Designation, olpasiran's uptake is projected to be medium-fast, with an estimated probability-adjusted peak share of 3.5% roughly seven years post-launch, and a potential US launch anticipated in 2027.

Other notable candidates include Obicetrapib (TA-8995) from NewAmsterdam Pharma and Menarini Group, a CETP inhibitor in Phase III whose EMA Marketing Authorization Application was validated in September 2025. Apabetalone (RVX000222) from Resverlogix, a BET inhibitor, is also progressing through Phase III for atherosclerosis and coronary artery disease. Additional programs include pelacarsen from Ionis Pharmaceuticals/Novartis, with Phase III data expected in early 2026, and lerodalcibep from LIB Therapeutics, which published positive Phase III HoFH data in early 2025.

Atherosclerotic Cardiovascular Disease Pricing and Regional Dynamics

Pricing remains an important lever shaping treatment adoption. Ezetimibe, priced at approximately USD 3 per tablet as a once-daily dose, carries an estimated annual cost of USD 1,104, while bempedoic acid — priced at roughly USD 11 per tablet — costs approximately USD 3,991 annually. These pricing benchmarks serve as important analogues for assessing the commercial positioning of emerging therapies.

Regionally, the US holds the largest ASCVD market share among the 7MM, with Germany as the second-highest contributor among EU4 and the UK countries, while France ranks lowest. By 2036, statin therapies are expected to generate the highest revenue among emerging therapies in Japan. These patterns reflect broader Atherosclerotic Cardiovascular Disease (ASCVD) market trends toward multi-pathway innovation, expanding treatable populations through earlier intervention, and a growing global cardiovascular disease burden that continues to sustain a large and durable market opportunity.

Atherosclerotic Cardiovascular Disease Market Outlook

With oral PCSK9 inhibitors, RNA-based Lp(a) therapies, anti-inflammatory agents, and gene-editing approaches advancing through clinical development, the ASCVD therapeutics landscape is poised for significant transformation over the coming decade. As payers increasingly align around advanced lipid-lowering therapies and next-generation agents approach commercialization, stakeholders will need to closely track evolving reimbursement frameworks, pricing analogues, and KOL perspectives to fully capitalize on this expanding opportunity.

Latest Reports

blood glucose monitoring systems market | erectile dysfunction market | hypotrichosis market | mouth neoplasms market | noonan syndrome market | orthopedic power devices market | periodontal disease market | babesiosis market | glp-1 agonists market | panic disorder market | celiac disease market | spinal implants market | thrombotic thrombocytopenic purpura market | vulvar squamous cell carcinoma market | zika virus market | advanced wound care market | donohue syndrome market | ftase inhibitor market | glabellar frown lines market | h3n2 infection market | insulin glargine biosimilar | meniere's disease market | post-transplant lymphoproliferative disorder market | anaphylaxis market |